Tue, 19th Jan 2016 12:48
AIM-listed drug developer Summit, which develops therapies for Duchenne Muscular Dystrophy and C. difficile infection, on Wednesday said its chief executive Glyn Edwards had acquired 30,000 shares. The 104.5p-a-share deal cost Edwards £31,350 and took his stake in the group to 233,333 shares. The
Read moreLONDON (Alliance News) - Summit Corporation PLC Tuesday said it will seek shareholder permission for a share consolidation that will see every 20 existing shares consolidated into one new share. In a statement, the drug discovery company said it will first consolidate every 20 shares into o
Read moreShares in Summit Corporation suffered a fall despite giving a generally positive report of the first phase of its Duchenne Muscular Dystrophy (DMD) trial which has examined the safety and tolerance of SMT C1100. The decline may be linked to a delay in the next patient study, which is expected to no
Read more